Bozeman, Montana (March 14, 2005) – Golden Helix Inc. announced today the release of ChemTree® v4.0 for Mac OS X. Based on recursive partitioning, ChemTree is the best predictor of which compounds to build or buy next in order to decrease downstream attrition rates.
Pipelines are thin for many drug discovery companies. The bar of approval for new medicines is continually rising because new treatments require higher efficacy and/or a better safety profile than current drugs on the market. As a result, approvals of new molecular entities have been steadily declining since 1996. ChemTree addresses this challenge by selection compounds with a better chance of gaining regulatory approval.
“In every head to head comparison that we and our customers have made, ChemTree has outperformed the competition both in terms of accuracy and generalization of compound activity predictions beyond the initial training set," commented Christophe Lambert, CEO of Golden Helix, Inc. "We’re excited to extend this capability to Apple users.”
“The performance, stability and ease-of-use provided by Mac OS X have led to strong adoption for the platform in the biotech and pharmaceutical markets,” said Ron Okamoto, Apple’s vice president of Worldwide Developer Relations. “We’re delighted that the combination of ChemTree’s advanced capabilities and Mac OS X innovation will greatly accelerate drug discovery research.”
ChemTree’s intuitive GUI conforms to the familiar Apple interface and allows the straightforward interpretation and communication of scientific results.
ChemTree empowers the chemoinformatics scientist to:
Reduce clinical failures through better discovery:
- Weed out failures before they enter clinical trials by optimizing for efficacy, safety and ADMET earlier
- Reduce attrition rate of compounds in later stages of pipeline using multivariate recursive partitioning to optimize for efficacy, safety and ADME simultaneously
Save time and resources by prioritizing what to screen next:
- Accelerate drug discovery by providing 10-100 fold hit rate increases on compounds cherry-picked from 3rd party vendors, combinatorial libraries, and internal compound collections
- Generate nanomolar concentration leads with the sequential screening process
- Maximize hit rates through focused combinatorial synthesis
- Automate screening analysis tasks to accelerate the drug discovery pipeline
- Resurrect failed screening attempts
Uncover QSAR relationships to accelerate lead optimization:
- Give lead optimization chemists a jump start by automatically highlighting the 'business end' of a molecule
- Reap maximum returns from screening investment by learning from both active and inactive compounds
- Accelerate the identification of lead series through structure/activity clustering
- Gain deeper chemical insight by automatic detection of interacting molecular features
- Derive value from noisy HTS data using ensemble averaging of many RP trees
About Golden Helix, Inc.
Founded in 1998 in Bozeman, MT, Golden Helix is a leading provider of data analysis software products and services designed to accelerate life science research and increase pharmaceutical R&D productivity. The company's products enable hundreds of researchers at the world's top pharmaceutical, biotech and non-profit research organizations to discover the genes that cause disease, improve target and lead discovery processes, and advance pharmacogenetic initiatives. Its products have been cited in nearly 100 peer reviewed publications that detail ground-breaking research for discovering the genetic and environmental basis of disease and creating safer and more effective medicines.
Golden Helix is committed to Accelerating the Quest for Significance.
For more information, please visit www.goldenhelix.com.
Director of Marketing
Golden Helix, Inc.